Tranzactioneaza Acadia Pharmaceuticals (US.ACAD) - 14.78 USD (%) Tranzactioneaza
Indici
Descriere companie
Acadia Pharmaceuticals Inc. (http://www.acadia-pharm.com/) is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).